2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s, Boehringer’s Phase 3 IPF data, Stanford’s TGF-β work in cardiovascular fibrosis, to over $3B in deals from Lilly, GSK, and others, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift.
Access this year’s incredible lineup of speakers
Join us this year to:
- Unlock novel targets with advances in single-cell and spatial omics, immune-stromal interactions, and cross-tissue mechanisms, featuring insights from Harvard Medical School, Gilead Sciences, and AdaptVac
- Strengthen translational confidence with precision-cut tissue slices, 3D models, and AI-driven biomarker strategies to bridge the gap between preclinical promise and clinical success
- Design winning clinical programs with lessons from recent Phase 2 data, including Resmetirom’s approval for MASH fibrosis and emerging IPF signals from GRI Bio and Redx Pharma
- Navigate the evolving landscape with expert perspectives on combination therapies, GLP-1 competition, and investor priorities to position your pipeline for partnerships and approvals
Don’t miss out – invite your colleagues to join you and take advantage of our early bird rates and group savings!